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European Journal of Cardio-thoracic Surgery 38 (2010) 391—393Aortic valve stenosis (AS) is the most common acquired
heart disease in the elderly and, because of the aging
population, its incidence increased noticeably during the last
decades [1,2]. The treatment of choice for patients carrying
a severe symptomatic AS remains the open heart surgery for
standard aortic valve replacement (AVR) with mean or mini-
sternotomy, cardiopulmonary bypass, aortic cross-clamping
and a valid cardioplegic arrest [3]. Advantages of this
procedure are the full ablation of the diseased native aortic
valve, the implantation of a reliable patient-matched
biological aortic prosthesis and the evidence of very
satisfactory mid-term and long-term results with low
mortality and morbidity [4—8]. However, the elderly with
concomitant severe comorbidities, left ventricular dysfunc-
tion and a critical preoperative state due to acute low
cardiac output, carry a higher surgical risk with increased
operative mortality and risk of onset of severe postoperative
complications, such as renal or pulmonary insufficiency
[5,6,9].
Hence, the very recent advent of transcatheter aortic
valve therapies with minimal access procedures is most
welcome in such a complex setting [10,11].
In fact, during the last decades, and in the absence of
available transcatheter stent-valve therapies, alternative
non-surgical procedures and medical protocols were pro-
posed for the treatment of high-risk patients with severe AS
and acute cardiac decompensation, judged as temporary
inoperable patients. In particular, these procedures were
developed to identify and treat, at first, the cause of the low
cardiac output, and, subsequently, to improve the clinical
and the hemodynamic effects of the AS and recovery the
myocardial function before performing standard AVR.
The percutaneous balloon aortic valvuloplasty (BAV),
performed few weeks before a standard AVR in temporary
inoperable patients, seemed to be, at that time, an
attractive alternative to urgent high-risk AVR, although a
limited long-term valve function [12,13].
Doguet et al., in their limited series of 25 patients treated
consequently with percutaneous BAV and standard surgical
AVR, between 2002 and 2006, propose to re-introduce the
primary BAV as an alternative bailout procedure in unstable,
temporary inoperable, AS patients [14].1010-7940/$ — see front matter # 2010 European Association for Cardio-Thoracic
doi:10.1016/j.ejcts.2010.08.035However, this approach has to be questioned with regard
to efficiency and appropriateness.
In fact, percutaneous BAV carries some intrinsic risks
related to the procedure itself, such as aortic valve
regurgitation, peripheral vascular damages or calcium
dislodgment from the valve leaflets. In addition, the
hemodynamic results are, sometimes, not as good as required
with no or little advantages for the patient in terms of
improved left ventricular function, mean trans-valvular
gradient and ameliorated aortic surface area [12—14].
Unfortunately, patients exposed to urgent BAV (and to the
risk related to the procedure) with absence of post-BAV
clinical improvements require further hospitalizations with
dedicated medical treatments before undergoing surgical
AVR, or need urgent valve replacement because of the
hemodynamic deterioration.
Furthermore, percutaneous BAV has some technical
limitations, such as the presence of severe peripheral
vascular disease (typically in the elderly), and not all
patients are good candidates for this ‘bridge-to-AVR’ trans-
vascular procedure, as well underlined by Doguet et al. in
their paper [14].
In such complex scenarios, the new transcatheter aortic
valve implantation (TAVI) therapies have great potential and
in many centers the implantation of transcatheter stent-
valves, either through a transfemoral or a transapical access,
has become a ‘routine’ procedure with encouraging early end
mid-term results [15,16].
Thus, in the era of transcatheter stent-valves the
treatment of decompensate aortic stenosis may be stratified
as follows.
1. First scenario: elderly patient with AS and
cardiogenic shock
1.1. The patient fulfils the guidelines for TAVI (high-
grade risk score) [3]
Primary TAVI, consisting of BAV plus stent-valve implanta-
tion under rapid pacing (Fig. 1), either via a transapical or a
transfemoral access, represents, in this setting, the idealSurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Fluoroscopy views taken during a transapical TAVI. The balloon aortic
valvuloplasty (A) is performed immediately before the stent-valve implanta-
tion (B).strategy for elderly patients with decompensate isolated AS
carrying an high logistic euroSCORE (above 20%), and suitable
for a biological heart valve implantation. In fact, once the
technical skills are acquired by the team, primary TAVI in
unstable high-risk patients is the logical step-forward instead
of performing percutaneous BAV as a bridge to open AVR. In
our 2-year clinical experience with transapical TAVI (62
cases), 5% of patients were in critical preoperative state with
severely decompensate AS and low cardiac output [17]: in all
but one patients, the hemodynamic improved remarkably
immediately after the stent-valve implantation with
decreased inotropic drug infusions, improved mean blood
pressure and improved left ventricular function.
1.2. The patient does not full-fills the guidelines for TAVI
[3]
Patients with e.g. apical thrombus and severe peripheral
vascular disease are not suitable for any kind of TAVI (the
trans-subclavian pathway remains, at the time being, an off-
label use). In this rare scenario, a standard AVR in urgency
remains a valid option but, alternatively, a bailout percu-
taneous BAV performed through a subclavian or a humeralaccess prior to standard AVR can be also taken into
consideration.
2. Second scenario: younger patient with AS and
cardiogenic shock
Despite frequent surgical exceptions in the clinical
practice, younger patients with isolated AS and low logistic
euroSCORE (below 20%) are not yet considered good
candidates for TAVI because of the unknown durability of
the available implants. The following clinical situations
should be distinguished.
2.1. Young AS patient in cardiogenic shock without multi
organ failure (low-grade risk score) and resistant to the
optimal medical therapy
This scenario requires a standard AVR in urgency with a
mechanical heart valve implantation. Following our experi-
ence, the standard operation is well tolerated and the
patient recovery will benefit from the hemodynamic
ameliorated after the valve replacement. AVR performed
in urgency requires optimal strategic thinking from the
surgeon and a valid team-work involving the surgeon, the
anesthesiologist and the intensive care unit team. In case of
concomitant disease (e.g. coronary disease or dilated
ascending aorta), the procedure can be performed con-
temporarily.
2.2. Young AS patient in cardiogenic shock and multi
organ failure
In this critical situation, the use of cardiopulmonary
bypass for surgical AVR is not encouraged and urgent BAV for
restoration of the patient’s hemodynamic, appears to be an
option as long as no randomized trial is available. However,
an urgent transapical or transfemoral TAVI has also to be
taken into consideration as a rescue procedure in case of
failed BAV, or primarily.
Now, if we look at the Doguet’s series of patients treated
with a bailout BAV as a bridge to surgical AVR and limited
availability of transcatheter aortic stent-valves, we would
have to look at them differently today. All of them carry a
high-risk profile with a mean logistic euroSCORE of 18.6% and
the majority is certainly suitable for biological valve
prosthesis (mean age: 71.9 years). In particular, patients
presenting with pulmonary edema, global cardiac decom-
pensation, cardiogenic shock and syncope are good candi-
dates for TAVI. Only one case, the patient with a very low
ejection fraction (below 10%) did obviously not fit the
guidelines for TAVI and the urgent BAV was the procedure of
choice. One more patient underwent a Bentall procedure
and, also in this case, the BAV appears to be the suitable
treatment prior to replacement of the aortic valve and the
ascending aorta.
In conclusion, TAVI procedures are the logical evolution of
percutaneous BAV but, unlike the latter, they allow for a
rapid recovery of the patients’ valve hemodynamic, once the
stent-valve is in place (low trans-valvular gradient and
absent or trivial valve insufficiency).
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changing rapidly and we trust that new technologies will
further improve the outcome for our patients.
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